Sitagliptin/metformin

Sitagliptin/metformin
Combination of
Sitagliptin Dipeptidyl peptidase-4 inhibitor
Metformin Biguanide
Clinical data
Pregnancy
category
  • US: B (No risk in non-human studies)
    Routes of
    administration    		 Oral
    ATC code
    Legal status
    Legal status
    Identifiers
    KEGG

    Sitagliptin/metformin (trade name Janumet) is an anti-diabetic drug, being a combination drug of sitagliptin (a dipeptidyl peptidase-4 inhibitor) and metformin. It is used a third-line treatment for people who do not achieve control of their blood sugar with metformin alone, or after trying to add sulfonylurea, pioglitazone, or insulin to the treatment.[1]

    As of 2018 the combination was marketed under several brand names, including Efficib, Janmet, Januet, Janumet, Jznumet, Ristaben Met, Ristfor, Siglimet, Sitamet, Sitar-M, Sliptin-M, Treviamet, and Velmetia.[2]

    References

    1. ↑ Hayes, J; Anderson, R; Stephens, JW (2016). "Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy". Drug Design, Development and Therapy. 10: 2263–70. doi:10.2147/DDDT.S93076. PMC 4958358. PMID 27486305.
    2. ↑ "International brands for Sitagliptin/metformin". Drugs.com. Retrieved 3 September 2018.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.